DE10191398D2 - Drug conjugates with intracellularly active ligands - Google Patents

Drug conjugates with intracellularly active ligands

Info

Publication number
DE10191398D2
DE10191398D2 DE10191398T DE10191398T DE10191398D2 DE 10191398 D2 DE10191398 D2 DE 10191398D2 DE 10191398 T DE10191398 T DE 10191398T DE 10191398 T DE10191398 T DE 10191398T DE 10191398 D2 DE10191398 D2 DE 10191398D2
Authority
DE
Germany
Prior art keywords
drug conjugates
active ligands
intracellularly active
intracellularly
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10191398T
Other languages
German (de)
Inventor
Stefan Duebel
Frank Emmrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotectid GmbH
Original Assignee
Biotectid GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotectid GmbH filed Critical Biotectid GmbH
Priority to DE10191398T priority Critical patent/DE10191398D2/en
Application granted granted Critical
Publication of DE10191398D2 publication Critical patent/DE10191398D2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE10191398T 2000-04-18 2001-04-18 Drug conjugates with intracellularly active ligands Ceased DE10191398D2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE10191398T DE10191398D2 (en) 2000-04-18 2001-04-18 Drug conjugates with intracellularly active ligands

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10019157A DE10019157A1 (en) 2000-04-18 2000-04-18 Method for introducing ligands into living cells
PCT/DE2001/001495 WO2001078785A2 (en) 2000-04-18 2001-04-18 Active substance conjugates with intracellularly active ligands
DE10191398T DE10191398D2 (en) 2000-04-18 2001-04-18 Drug conjugates with intracellularly active ligands

Publications (1)

Publication Number Publication Date
DE10191398D2 true DE10191398D2 (en) 2003-04-30

Family

ID=7639155

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10019157A Withdrawn DE10019157A1 (en) 2000-04-18 2000-04-18 Method for introducing ligands into living cells
DE10191398T Ceased DE10191398D2 (en) 2000-04-18 2001-04-18 Drug conjugates with intracellularly active ligands

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10019157A Withdrawn DE10019157A1 (en) 2000-04-18 2000-04-18 Method for introducing ligands into living cells

Country Status (3)

Country Link
AU (1) AU7384401A (en)
DE (2) DE10019157A1 (en)
WO (1) WO2001078785A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1205191A1 (en) * 2000-11-13 2002-05-15 Centre National De La Recherche Scientifique Targeted modification of intracellular compounds
WO2007101202A1 (en) * 2006-02-27 2007-09-07 Research Development Foundation Cell-targeted ikb and methods for the use thereof
DE102007041834A1 (en) * 2007-09-03 2009-03-05 Siemens Ag Medicines for the treatment of a carcinoma
US20140065172A1 (en) * 2011-01-26 2014-03-06 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
EP4006052A1 (en) 2014-10-23 2022-06-01 Singh Molecular Medicine, LLC Single domain antibodies directed against intracellular antigens
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
TWI746473B (en) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 Single domain antibodies directed against intracellular antigens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0574395T3 (en) * 1990-11-09 2002-10-07 Stephen D Gillies Cytokine immunoconjugates
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
IT1271688B (en) * 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa HYBRID MOLECULES FOR ANTI-CANCER TREATMENT THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
ES2167391T3 (en) * 1994-09-16 2002-05-16 Merck Patent Gmbh IMMUNOCONJUGADOS II.
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2000045850A2 (en) * 1999-02-06 2000-08-10 Aurx Inc. Drug delivery vehicle
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain

Also Published As

Publication number Publication date
WO2001078785A2 (en) 2001-10-25
AU7384401A (en) 2001-10-30
WO2001078785A3 (en) 2002-05-10
DE10019157A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
NO20030627D0 (en) Hydrogel-driven drug dosage form
NO20022970D0 (en) Hydrogel-driven drug dosage form
NO20025729L (en) Ethylenedicycin (EC) drug conjugates
DE60118008D1 (en) PHARMACEUTICAL COMPOSITIONS WITH AMLODIPINMALEAT
DE60016271D1 (en) drug delivery
DE60120170D1 (en) INSECTICIDE BAG
EE05376B1 (en) Aqueous Suspension-containing Parenteral Pharmaceutical Formulation
DE60033176D1 (en) DRUG DONATION
DE60135657D1 (en) ABSORBENT ARTICLE WITH IMPROVED BEHAVIOR
DE69928085D1 (en) DOSAGE FORM WITH EXTENDED ACTIVE SUBSTANCE
DE60127002D1 (en) PHARMACEUTICAL COMPOSITION
NO20071303L (en) Pharmaceutical preparations
DE60209145D1 (en) PHARMACEUTICAL FORMULATIONS WITH PLATIN DERIVATIVES
DE50102752D1 (en) Fungicidal drug combinations
ATE366128T1 (en) PHARMACEUTICAL COMPOSITION
DE60142742D1 (en) VISZERALADIPOSEMESSGERÄT WITH BODY WEIGHING FUNCTION
DE50003274D1 (en) BUILT SYNCHRONIZED BODY WITH STOP ELEMENT
DE10191398D2 (en) Drug conjugates with intracellularly active ligands
DE60143148D1 (en) EN WITH HONEYWAVES
DE60136367D1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED CARRIER
DE10196460T1 (en) Selbstzerstör syringe
DE60018760D1 (en) NEEDLE
IS6163A (en) drugs Komplex
SE0004677D0 (en) Intraaxonal drug administration
BR0101932B1 (en) disposable absorbent article with leakage barriers.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8131 Rejection